Zanoterone

CAS No. 107000-34-0

Zanoterone( —— )

Catalog No. M36136 CAS No. 107000-34-0

Zanoterone is an AR antagonist (androgen receptor).Zanoterone has antitumor activity for the treatment of genitourinary disorders and oncological disorders and may be used in the study of prostate cancer.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 456 In Stock
10MG 653 In Stock
25MG 1026 In Stock
50MG 1376 In Stock
100MG 1851 In Stock
200MG Get Quote In Stock
500MG 3646 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Zanoterone
  • Note
    Research use only, not for human use.
  • Brief Description
    Zanoterone is an AR antagonist (androgen receptor).Zanoterone has antitumor activity for the treatment of genitourinary disorders and oncological disorders and may be used in the study of prostate cancer.
  • Description
    Zanoterone is an AR antagonist (androgen receptor).Zanoterone has antitumor activity for the treatment of genitourinary disorders and oncological disorders and may be used in the study of prostate cancer.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Endocrinology/Hormones
  • Target
    Androgen Receptor (AR)
  • Recptor
    Androgen Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    107000-34-0
  • Formula Weight
    416.58
  • Molecular Formula
    C23H32N2O3S
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C[C@@]12[C@@]3([C@]([C@]4([C@](C)(CC3)[C@@](C#C)(O)CC4)[H])(CC[C@]1(CC=5C(C2)=CN(S(C)(=O)=O)N5)[H])[H])[H]
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • ARN-509

    ARN-509 is a selective and competitive androgen receptor inhibitor with IC50 of 16 nM in a cell-free assay, useful for prostate Y treatment.

  • 2-hydroxy Flutamide

    2-hydroxy Flutamide is competitive inhibition of androgen receptor (AR)?for the treatment of prostate cancer.

  • LGD-4033

    A novel nonsteroidal, oral selective androgen receptor modulator (SARM), binds androgen receptor with high affinity (Ki=1 nM) and selectivity.